TBPH Stock Recent News

TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Company Participants Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - Senior VP & CFO Rhonda F. Farnum - Chief Business Officer and Senior VP of Commercial & Medical Affairs Rick E.

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.13 per share a year ago.

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year 1 Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summer Completed sale of TRELEGY ELLIPTA royalty interest to GSK for $225 million TRELEGY year-to-date sales on track to trigger $50 million milestone in 2025 Strong balance sheet with $339 million in cash and no debt DUBLIN , Aug. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the second quarter of 2025. "Strong execution across our business defined the second quarter, driven by commercial growth, disciplined operations, and continued progress on ampreloxetine.

DUBLIN , July 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2025 financial results and provide a business update after market close on Tuesday, August 12, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT / 9:00 pm GMT) that day.

DUBLIN , July 23, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference.

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

YUPELRI approved by China's NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD Approval triggers $7.5 million milestone payment from Viatris, with eligibility to receive further sales milestones and tiered royalties on net sales in China Theravance Biopharma incurs no commercial costs in China; Viatris is responsible for the launch and commercialization DUBLIN , June 26, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that Viatris Inc. ("Viatris"), has secured regulatory approval from China's National Medical Products Administration (NMPA) for YUPELRI® (revefenacin) inhalation solution, the first once–daily nebulized long–acting muscarinic antagonist (LAMA) approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in China. This approval triggers a one-time $7.5 million milestone from Viatris to Theravance Biopharma, which is expected to be received in Q3 2

Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.

Definitive agreement to result in one-time $225 million cash payment  Theravance Biopharma retains  rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved $225 million from royalty transaction announced today,  in addition to the $1.1 billion upfront received in 2022 , and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billion First outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value ; Board remains  committed to returning excess capital to shareholders DUBLIN , June 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta ("T